APEIRON Capital Ltd Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Summit Therapeutics
SMMT
|
+$27.4M |
| 2 |
iShares Bitcoin Trust
IBIT
|
+$8.04M |
| 3 |
Qfin Holdings
QFIN
|
+$4.78M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GraniteShares ETF Trust GraniteShares 2x Long NVDA Daily ETF
NVDL
|
+$71.1M |
| 2 |
Tesla
TSLA
|
+$18.8M |
| 3 |
Amazon
AMZN
|
+$15.6M |
| 4 |
On Holding
ONON
|
+$10.4M |
| 5 |
NetEase
NTES
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 33% |
| 2 | Financials | 22.39% |
| 3 | Healthcare | 21.87% |
| 4 | Technology | 16.41% |
| 5 | Communication Services | 0% |
Similar funds
APEIRON Capital Ltd's Q2 2025 Portfolio in Review
As of Q2 2025, APEIRON Capital Ltd held 13 positions worth $106M, down 51% from $218M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
APEIRON Capital Ltd withdrew a net $108M in Q2 2025, closing 8 positions and reducing 2 holdings. Its most notable exit was GraniteShares ETF Trust GraniteShares 2x Long NVDA Daily ETF, an estimated $71.1M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 33% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
Against the trend, APEIRON Capital Ltd opened a new position in Summit Therapeutics worth $23.2M.
- APEIRON Capital Ltd's largest Q2 2025 buy was Summit Therapeutics: 1,200,941 shares worth $23.2M.
- APEIRON Capital Ltd added most to Qfin Holdings in Q2 2025, an estimated $4.78M increase.
- APEIRON Capital Ltd's biggest Q2 2025 reduction was On Holding, cutting an estimated $10.4M.
- APEIRON Capital Ltd fully exited GraniteShares ETF Trust GraniteShares 2x Long NVDA Daily ETF in Q2 2025, selling an estimated $71.1M.
- APEIRON Capital Ltd's ten largest holdings make up 100% of its $106M portfolio in Q2 2025.
- APEIRON Capital Ltd opened 2 new positions and closed 8 in Q2 2025.
- APEIRON Capital Ltd's portfolio value fell 51% quarter-over-quarter to $106M.
Based on APEIRON Capital Ltd's 13F filing for Q2 2025, filed 25 Jul 2025.